Cryton Biosciences
ActiveCryton Biosciences is developing a first-in-class dual-action drug that restores mitochondrial function in immune AND cancer cells resulting in tumor death.
What it does
Cryton Biosciences is a lifetech company focused on addressing mitochondrial dysfunction, a critical factor in tumor growth and immune cell exhaustion. The company is developing a first-in-class dual-action drug that restores mitochondrial function in both immune and cancer cells, leading to immunogenic tumor death. This approach rewires tumor metabolism to induce stress and cell death while reversing immune exhaustion to enhance anti-cancer activity. The lead drug candidate, CB-101, has demonstrated robust anti-tumor efficacy in preclinical models of colorectal cancer and melanoma, including durable complete responses and enhanced effects when combined with standard chemotherapy. A patient selection strategy has been defined to target populations with high unmet medical needs. Cryton Biosciences has advanced a portfolio of optimized compounds and secured intellectual property protection for its lead chemical series. The company’s innovative dual-action mechanism represents a significant advancement in cancer therapeutics by simultaneously targeting tumor cells and revitalizing immune responses.
Its site says now · captured 2026-08-26
Cryton - Redefining Cancer Treatments Through Mitochondrial Medicine
At Cryton Biosciences, we believe cancer originates not only from DNA mutations but also from disruptions in mitochondrial function.
Next to it in Healthcare and bio · mitochondrial-targeting cancer therapeutics
- FinalDoseY Combinator X26
Programmable DNA drug destroying all cancers, unlocking 80% of targets
- FREZENT Biological SolutionsSOSV SOSV IndieBio NY 07
Changing the prognosis for patients with advanced stage cancer
- Adipo TherapeuticsPlug and Play PnP 2026
Adipo Therapeutic is a biotechnology company that is developing a novel asset for the treatment of obesity by increasing energy expenditure via mitochondria biogenesis and activation in white adipose tissue (fat browning).
- Bahto BiosciencesPlug and Play PnP 2026
Bahto Biosciences develops non-opioid small-molecule therapeutics for painful peripheral neuropathy, a condition with limited effective treatment options that afflicts more than 19 million Americans.
- Diapin TherapeuticsPlug and Play PnP 2026
Novel Therapies for Cardiovascular and Metabolic Diseases
- RNARevivePlug and Play PnP 2026
RNARevive is developing a next-generation RNA platform that enables long-lasting, low-dose protein therapeutics. Our lead candidates tackle the anti-aging and longevity space, targeting osteoporosis, age-related macular degeneration (AMD), and liver diseases.
- TareBioY Combinator S26
Vaccines for any cancer or infection in weeks.
- Scioto BiosciencesPlug and Play PnP 2025
Scioto is a preclinical stage company developing innovative therapies devoted to having a transformative impact.